Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

NDA FilingALXN1840Positive

AI Analysis

Summary

Monopar Therapeutics initiated a rolling New Drug Application (NDA) submission for ALXN1840 in Wilson Disease, advancing the drug toward regulatory review.

Outcome Details

Rolling NDA submission initiated

Importance:7/10

Sentiment:

0.60

NDA_submissionWilson_Diseaseregulatory_progressrolling_submission

Related Companies

$MNPR

Read the original article

Published by Drugs.com New Drug Applications on July 22, 2026 9:07 PM

Read Original